Vanguard Capital Management’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
Other funds holding FHTX
EC
SL
Vanguard Capital Management's FHTX Position: Q3 2026 in Review
Vanguard Capital Management increased its Foghorn Therapeutics (FHTX) stake by 6.1% in Q3 2026, buying an estimated $482K and bringing the position to 1,586,219 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3036.
Vanguard Capital Management first reported a position in FHTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.29M in Q2 2026. 121 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.
- Vanguard Capital Management held 1,586,219 shares of Foghorn Therapeutics worth $5.66M as of Q3 2026.
- Vanguard Capital Management bought 91,608 Foghorn Therapeutics shares in Q3 2026, an estimated $482K.
- Foghorn Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3036 holding.
- Vanguard Capital Management first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Foghorn Therapeutics position peaked at $7.29M in Q2 2026.
- 121 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.